Continued vutrisiran treatment for adults with heart disease from transthyretin amyloidosis
Studies vutrisiran in adults with transthyretin amyloidosis and heart muscle disease, continuing or switching treatment.
Key facts
- Who runs it
- Alnylam Pharmaceuticals
- Where
- Prague, CzechiaSee the siteAlso in 16 other countries, 72 sites
- Trial code
- Registry title
- A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Status
- Enrolling by invitation
- Phase
- Phase 3
- People taking part
- 700 people, planned
- Started
- 3 Dec 2024
- Expected to end
- 31 Mar 2028
- Type of study
- Interventional
- Treatments tested
- Vutrisiran
- Record updated
- 21 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with transthyretin amyloidosis with heart muscle disease who took part in earlier patisiran or vutrisiran studies.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Transthyretin amyloidosis (ATTR) with cardiomyopathy
- Earlier treatment
- Must be taking part in the patisiran parent studies ALN-TTR02-011 or ALN-TTR02-014, or have completed the 24-month OLE Period of the vutrisiran parent study ALN-TTRSC02-003
Main reasons for not taking part
- Stopped study drug for good during the parent studies ALN-TTR02-011, ALN-TTR02-014 or ALN-TTRSC02-003
- Plans to join another study of an investigational device or drug during this study
- Has other medical conditions that the investigator thinks would interfere with following the study or understanding the data
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients who are participating in the patisiran parent studies ALN-TTR02-011 or ALN-TTR02-014 or who have completed the 24-month OLE Period in the vutrisiran parent study ALN-TTRSC02-003
Who cannot take part
- Has permanently discontinued study drug administration while participating in the parent studies, ALN-TTR02-011, ALN-TTR02-014, or ALN-TTRSC02-003
- Future or current participation in another investigational device or drug study, scheduled to occur during this study
- Has other medical conditions or comorbidities which, in the opinion of the Investigator, would interfere with study compliance or data interpretation
Where in Czechia
Also in 16 other countries, 72 sites
- PragueHospital not named in the registryNo longer taking part
About the trial
What the trial wants to find out
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.
The group in the trial
- Vutrisiran 25 mgTreatment being tested
Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M).
Treatment: Vutrisiran
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
- Plain-language title
- Continued vutrisiran treatment for adults with heart disease from transthyretin amyloidosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 21 October 2026